ReNetx Bio
  • Home
  • About
  • Team
  • Technology
    • Publications
  • Clinical Trial
  • News
  • Contact

​

Picture
Recovery of function requires the regeneration and rewiring of neurons.  The major factors limiting regrowth are extracellular inhibitors in CNS tissue called Nogo-A, MAG and OMgp.  The company has developed a decoy receptor – called Nogo Trap - that binds the growth inhibitors allowing the body to grow nerve fibers naturally and directly targeting restoration across all facets of growth:  axonal regeneration (long distance), axonal sprouting (medium distance) and synaptic plasticity.  
​
The Nogo Trap technology has been validated in a number of independent academic and pharmaceutical industry laboratories to show significant regrowth.  The first indication addressed will be Chronic Spinal Cord Injury (SCI) followed by Acute SCI and glaucoma.   
​
Manufacturing/Regulatory - The company has completed GMP manufacturing and toxicology testing and has received U.S. FDA authorization to proceed with a Phase 1/2 trial in patients with chronic spinal cord injury.

Patents - The company has licensed patents from Yale University and industry partners with protection for composition of matter as well as methods of use. 

​Aug 4, 2017 (Video by Ed Stannard--New Haven Register)
Dr. Stephen Strittmatter, professor of neurology and neuroscience at the Yale
School of Medicine and founder of ReNetX Bio Inc., talks about a new therapy
​ to repair severed nerves in the central nervous system. 
© COPYRIGHT 2019. ALL RIGHTS RESERVED.
  • Home
  • About
  • Team
  • Technology
    • Publications
  • Clinical Trial
  • News
  • Contact